Please use this identifier to cite or link to this item:
|Title:||Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults|
|Authors:||Tim R. Cressey|
Jennifer R. King
Vincent J. Carey
Edward P. Acosta
|Abstract:||© 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.|
|Appears in Collections:||CMUL: Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.